文献速递淋巴瘤血栓与止血

西方大型队列中TAFRO综合征特征:一项回顾性研究

Characteristics of thrombocytopenia, anasarca, fever, reticulin fibrosis and organomegaly syndrome: a retrospective study from a large Western cohort.
PubMed 文献 · Br J Haematol · 2021-09-28

该回顾性研究描述了首个大型西方TAFRO综合征队列(n=25),患者符合全日本TAFRO综合征研究组诊断标准,并与iMCD-NOS患者(n=43)对照。结果显示西方TAFRO患者基线特征与既往报道一致,但结局并不比iMCD-NOS更差;两组在治疗选择、利妥昔单抗(71% vs 67%)或托珠单抗(69% vs 91%)应答上无显著差异,两年总生存率均高于95%。

要点

  • 西方TAFRO综合征患者结局并不比iMCD-NOS患者更差。
  • 利妥昔单抗和托珠单抗应答率在两组间无显著差异。
  • 两组两年总生存率均高于95%。

核心结论

  • 西方TAFRO综合征患者尽管基线特征与既往报道一致,但结局并不比iMCD-NOS患者更差。
  • 研究结果对TAFRO实体在西方国家的独特性提出疑问。

研究设计与样本

  • 回顾性研究,纳入首个大型西方TAFRO综合征队列(n=25),符合全日本TAFRO综合征研究组诊断标准。
  • 对照组为iMCD-NOS患者(n=43)。

主要发现

  • TAFRO与iMCD-NOS两组在治疗选择上无显著差异。
  • 利妥昔单抗应答率在TAFRO和iMCD-NOS分别为71%和67%,无显著差异。
  • 托珠单抗应答率在TAFRO和iMCD-NOS分别为69%和91%,无显著差异。
  • 两组两年总生存率均高于95%。

关键数值与推荐

  • TAFRO综合征诊断采用全日本TAFRO综合征研究组诊断标准。
  • 利妥昔单抗应答率:TAFRO 71% vs iMCD-NOS 67%。
  • 托珠单抗应答率:TAFRO 69% vs iMCD-NOS 91%。
  • 两年总生存率两组均高于95%。

临床怎么用

  • 西方TAFRO综合征患者可采用与iMCD-NOS类似的治疗策略,利妥昔单抗和托珠单抗均显示应答。
  • TAFRO诊断标准的纳入和排除界限仍需进一步明确。

局限性

  • 回顾性研究设计。
  • 样本量有限(TAFRO n=25,iMCD-NOS n=43)。
  • TAFRO定义中纳入和排除标准的界限存在讨论空间。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Idiopathic multicentric Castleman disease (iMCD) is a non-clonal inflammatory lymphoproliferative disorder of unknown origin. Recently, TAFRO syndrome (thrombocytopenia, anasarca, fever, reticulin fibrosis and organomegaly) emerged as a singular variant of iMCD in Asia and was associated with a severe course and a poor outcome. The present study describes the first large Western cohort of TAFRO syndrome patients (n = 25) meeting the All Japan TAFRO Syndrome Research Group diagnostic criteria. Characteristics of TAFRO patients were compared to iMCD-not otherwise specified (iMCD-NOS) patients used as a control group (n = 43). Our results show that despite baseline characteristics in accordance with previously reported series, Western TAFRO syndrome patients do not appear to present with a worse outcome than iMCD-NOS patients. There were no significant differences between the two groups regarding treatment choice, response to rituximab (71% vs. 67%) or tocilizumab (69% vs. 91%) in TAFRO and iMCD-NOS, respectively. The two-year overall survival was above 95% in both groups. Limits of inclusion and exclusion criteria for TAFRO definition are also discussed. Our findings raise the question of the singularity of the TAFRO entity in Western countries. The data should promote further research using unsupervised models to identify markers of disease severity in Western cohorts of iMCD patients.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Maisonobe L, Bertinchamp R, Damian L, et al. Characteristics of thrombocytopenia, anasarca, fever, reticulin fibrosis and organomegaly syndrome: a retrospective study from a large Western cohort. Br J Haematol. 2021. PMID: 34585382. doi:10.1111/bjh.17868

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。